• Microbix is reviewing 50% U.S. tariffs on Canadian products taking effect at 12:01 a.m. on October 30, 2026.
• QAPs products appear covered by tariffs targeting diagnostic and laboratory reagents; U.S. buyers or importers will pay the duties.
• QAPs generated C$ 4.2 million over nine months through June 30, 2026, including C$ 3.4 million from U.S. clients.
• Total revenue from U.S. clients reached C$ 5.5 million over the same period.
• Persistent tariffs could prompt U.S. customers to seek cost-sharing or domestic suppliers, despite validation requirements limiting ready substitutes for QAPs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microbix Biosystems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610280700ACCESSWRNAPR_____1242637) on October 28, 2026, and is solely responsible for the information contained therein.